<code id='9DC7F67900'></code><style id='9DC7F67900'></style>
    • <acronym id='9DC7F67900'></acronym>
      <center id='9DC7F67900'><center id='9DC7F67900'><tfoot id='9DC7F67900'></tfoot></center><abbr id='9DC7F67900'><dir id='9DC7F67900'><tfoot id='9DC7F67900'></tfoot><noframes id='9DC7F67900'>

    • <optgroup id='9DC7F67900'><strike id='9DC7F67900'><sup id='9DC7F67900'></sup></strike><code id='9DC7F67900'></code></optgroup>
        1. <b id='9DC7F67900'><label id='9DC7F67900'><select id='9DC7F67900'><dt id='9DC7F67900'><span id='9DC7F67900'></span></dt></select></label></b><u id='9DC7F67900'></u>
          <i id='9DC7F67900'><strike id='9DC7F67900'><tt id='9DC7F67900'><pre id='9DC7F67900'></pre></tt></strike></i>

          Home / explore / focus

          focus


          focus

          author:hotspot    Page View:8

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In